Germany Non-Invasive Prenatal Testing Market Market Report 2023 to 2030

Germany Non-Invasive Prenatal Testing Market Analysis

$ 3999

Germany Non-Invasive Prenatal Testing Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 - 2033. The market for Non-Invasive Prenatal Testing is expanding as a result of rising healthcare spending and increasing demand for non-invasive methods for prenatal testing in both developed and developing nations. This demand is fueling the development of better tools and methods for the early detection and assessment of genetic disorders in developing fetuses. Some of the key players in the global Non-Invasive Prenatal Testing Market include Illumina, Inc., Thermo Fisher Scientific Inc., General Electric, BGI Group, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Laboratory Corporation of America Holdings, Natera, Inc., Yourgene Health, Eurofins LifeCodexx GmbH, Quest Diagnostics Incorporated, Myriad Genetics Inc., NIPD Genetics, and Next Biosciences.

ID: IN10DEHS079 CATEGORY: Healthcare Services GEOGRAPHY: Germany AUTHOR: Dr. Nensi Savani

Buy Now

Germany Non-Invasive Prenatal Testing Market Executive Summary

Germany Non-Invasive Prenatal Testing Market is valued at around $175.7 Bn in 2022 and is projected to reach $588 Bn by 2030, exhibiting a CAGR of 16.3% during the forecast period 2023-2030.

The Non-Invasive Prenatal Testing Market refers to the market for prenatal testing which is used to detect specific chromosomal abnormalities in fetuses and it is non-invasive and safe diagnostic testing. Improvements in the reimbursement environment and high demand for early Non-Invasive Prenatal Testing (NIPT) are the major factors projected to drive market expansion over the forecast period.

The increased prevalence of genetic disorders and increasing population have contributed to the growth of the global market for Non-Invasive Prenatal Testing in recent years. Advancements in diagnostic technologies, such as expanding screening panels, detection of subchromosomal abnormalities, and twin gestation technique are also driving the market.

There are many players in the global Non-Invasive Prenatal Testing market but firms like. Illumina, Inc., Thermo Fisher Scientific Inc., General Electric, BGI Group, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Laboratory Corporation of America Holdings, Natera, Inc., Yourgene Health, Eurofins LifeCodexx GmbH, Quest Diagnostics Incorporated, Myriad Genetics Inc., NIPD Genetics, and Next Biosciences are some of the major players in the Market.

Significant technological developments have improved testing capability. Many well-known companies and fresh start-ups are looking for financing to carry out non-invasive prenatal testing technique development and clinical testing. Government and business organizations are searching for research facilities and start-ups to provide cutting-edge testing methods to identify critical genetic abnormalities through non-invasive prenatal testing.

Technological advancements, increasing demand for non-invasive methods, and increasing maternal age are projected to fuel the market of non-invasive prenatal testing in the coming years. The market still has difficulties with regard to obtaining regulatory permission, High cost, and less skilled professionals.

Market Dynamics

Drivers of Germany Non-Invasive Prenatal Testing Market:

Increasing Maternal Age: Maternal aging can result in a number of health problems, including decreased fertility, high blood pressure, and an increased risk of miscarriage, stillbirths, and maternal mortality. The incidence of genetic disorders in neonates can also grow with maternal age as a result of improper chromosomal division. These findings reflect a global rise in maternal advanced age, which is expected to result in greater health problems. So, it is anticipated that the increasing maternal age and prevalence of chromosomal abnormalities will increase the demand for non-invasive prenatal testing.

Increasing Prevalence of Genetic Disorders: The market is experiencing organic revenue growth due to an increase in chromosomal abnormalities and increased product usage in new applications. The development of existing tests with improved capability, better chemistry, and bioinformatics analysis is also expected to fuel market expansion. One of the main factors affecting the industry is the improvement of payment policies for routine and low-risk pregnancies.

Non-Invasive Nature: It is a non-invasive and safe procedure for diagnosis and it does not involve any radiation. Because of its safety and non-invasive nature, it targets a larger group of pregnant women which has given rise to the non-invasive prenatal testing Market.

Notable Deal in Non-Invasive Prenatal Testing Market:

In January 2022, QIAGEN and Atila Biosystems entered into collaborations to provide non-invasive prenatal testing (NIPT) services to the company's dPCR business.

In February 2022, the FDA authorized a brand-new NIPT test called Panorama Plus. This test can identify microdeletions and microduplications as well as Down syndrome, Edwards syndrome, Patau syndrome, and Turner syndrome.

In March 2022, the American College of Obstetricians and Gynecologists (ACOG) revised its recommendations for NIPT. All pregnant women should be offered NIPT, regardless of their age or risk factors, according to the new guidelines.

In April 2022, a study that was published in the journal Nature Genetics revealed that NIPT can be used to identify more chromosomal abnormalities than previously believed. According to the study, NIPT is capable of identifying more than 90% of Down syndrome, Edwards syndrome, and Patau syndrome patients.

In May 2022, a study that was published in the journal JAMA Pediatrics revealed that NIPT is safe for expectant mothers and their unborn children. According to the study, NIPT had no negative side effects.

Key players

LifeCodexx AG Roche Diagnostics GmbH Eurofins LifeCodexx GmbH LifeLabs Genetics Centogene AG Premaitha Health (CooperSurgical) Igenomix Germany GmbH Sonic Genetics GmbH BGI Genomics GATC Biotech AG

1. Executive Summary
1.1 Service Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Healthcare Services Market in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Services
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For Germany Non-Invasive Prenatal Testing Market

By Method:

Ultrasound Detection
Biochemical Screening Tests
Cell-free DNA in Maternal Plasma Tests

By Test Type:

Materni21
Harmony
Panorama
Verify
NIFTY
Others

By Application:

Trisomy
Microdeletion Syndrome
Other Applications

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.